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Abstract. Background: The aim of the present prospective
case-control study was to evaluate the putative relevance of
circulating microparticles (MP) as a biomarker in breast
cancer patients. Materials and Methods: Endothelial cell-
(EMP) and leukocyte-derived MP (LMP) were determined by
flow cytometry in breast cancer patients (n=41) and healthy
controls (n=25) and compared to carcinoembryonic antigen
(CEA), cancer antigen (CA)15-3 and von Willebrand factor
antigen (vWF) levels by specificity-sensitivity profiles. Results:
LMP, CEA and CA15-3 levels differed significantly between
breast cancer patients and controls, whereas EMP and vWF
did not. The specificity-sensitivity profiles of LMP and CA15-
3 were similar. Conclusion: Increasing levels of circulating
LMP(CD45+), CEA and CA15-3 correlated with increasing
tumor size, thus reflecting disease stage. LMP showed an equal
specificity-sensitivity profile to the established marker CA15-3
and therefore might have the potential to become a new
biomarker in breast cancer patients.
About one million women worldwide are newly diagnosed
with breast cancer per year (1). The diagnostic tools to
identify women developing breast cancer are mammography,
magnetic resonance imaging and core biopsy. So far,
prognostic markers in breast cancer consist of histological
and biological factors, requiring the examination of tumor
tissue (2). For a long time, carcinoembryonic antigen (CEA)
was the only circulating biomarker used in patients with
breast cancer. Nowadays, cancer antigen (CA)15-3, a serum-
based product of the mucin1 gene, is the most widely used
biomarker for breast cancer (3). The main applications of
CEA and CA15-3 include the surveillance of breast cancer
patients as well as therapy monitoring in patients with
advanced disease (4). 
Recent investigations pointed out a possible clinical
relevance of circulating cell-derived microparticles (MP) in
different kinds of malignant diseases, including gastric
cancer (5), lung cancer (6), Trousseau's syndrome (7),
colorectal cancer (8), lymphomas (9, 10), and patients with
mucinous adenocarcinomas (breast and pancreatic cancer)
(11). However, it is unknown if circulating MP can be used
as a tumor marker in different types of cancer. 
In this prospective case-control study, the numbers of
circulating leukocyte-derived MP (LMP) and endothelial
cell-derived MP (EMP) were determined in breast cancer
patients. The specificity-sensitivity profiles of circulating
LMP and EMP were analyzed and compared to the CEA
and CA15-3 profiles. 
Recently, levels of von Willebrand Factor antigen (vWF), a
marker of endothelial cell activation, has been shown to
correlate with breast cancer progression (12). Therefore, the
levels of the vWF antigen were also determined and their
relation with circulating numbers of EMP was investigated. 
Materials and Methods
Study population. Newly diagnosed patients with histologically
proven breast cancer (n=41) were included before surgical
treatment. Afterwards, the patients were classified according to the
tumor, node, metastases (TNM) stages. The study group contained
patients with tumor size <2 cm (T1; n=22) and tumor size 2-5 cm
(T2; n=13). Most patients showed negative axillary nodes (26), and
a few patients presented with 1-2 (10), 3-5 (3) or more positive
nodes (2). Distant metastases were detected in six breast cancer
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patients. The healthy controls (n=25) had mammograms without
pathological findings within the last 12 months, did not smoke and
were not taking oral contraceptives or hormonal treatment. All the
participants were Caucasians. Signed informed consent was
obtained from all the participants, allowing analysis of all the
clinical and laboratory data mentioned in this paper. The Human
Investigation Review Board of the Ludwig-Maximilians-University
Munich approved the study.
Blood sampling and measurements. Blood samples were taken by
the same experienced medical student at the same time period (9
to 12 am) by puncture of the antecubital vein without tourniquet
through a 20-gauge needle. 
For MP analysis, platelet-poor plasma was prepared by
centrifugation at 1550xg for 20 minutes within 15 minutes after
collection. The plasma was then shock-frozen in liquid nitrogen for
15 minutes and stored at –80ÆC until assayed.
The CEA levels were quantified using a microparticle immuno-
enzymometric assay (Abbott Laboratories, Chicago, IL, USA) on
the AxSYM system. 
The serum levels of CA15-3 were determined by an
electrochemiluminescent immunoenzymometric assay (Roche
Diagnostics, Mannheim, Germany) by the Elecsys system. The
serum concentrations of vWF antigen were investigated in
randomly selected women of T1 (10), T2 (10) and M1 (6) as well as
healthy controls (10) by using latex-amplified immuno-turbidimetry
(Dade, Behring, Marburg, Germany). Additionally, hemoglobin
(g/dl) and leukocyte counts (Giga (G)/L) were measured in the
whole study population.
Reagents for microparticle analysis. Fluorescein isothiocyanate
(FITC)-labelled annexin V, phycoerythrin (PE)-labelled annexin
V, and IgG-PE were obtained from Immuno Quality Products
(Groningen, The Netherlands). Anti-E-selectin-PE was purchased
from BD Biosciences (Heidelberg, Germany), IgG-FITC from
Immunotech (Marseille, France), and anti-cluster of differentiation
(CD)144-FITC from Acris (Hiddenhausen, Germany). Anti-CD45-
PE was obtained from Immunotech. All the antibodies and annexin
V were diluted with phosphate-buffered saline (PBS; 154 mmol/l
NaCl, 1.4 mmol/l phosphate, pH 7.4). Final dilutions were: annexin
V-FITC 1:100 (v/v), annexin V-PE 1:200, anti-CD144-FITC 1:20,
anti-E-selectin-PE 1:20 and anti-CD45-PE 1:5. 
Isolation and identification of EMP and LMP. Isolation and analysis
were performed as described by Nieuwland et al. (13). In brief,
frozen plasma (250 Ìl) was slowly thawed on melting ice for
approximately one hour. After centrifugation at 17,570xg and 20ÆC
for 30 minutes, 225 Ìl of MP-free supernatant was taken off. 
The remaining MP pellet was diluted with 225 Ìl of PBS
containing 10.9 mmol/L trisodium citrate (PBS/citrate buffer),
resuspended and centrifuged again for 30 minutes at 17,570 xg and
20ÆC. Afterwards the supernatant (225 Ìl) was removed, 75 Ìl of
PBS/citrate buffer was added, and the MP pellet was resuspended
again. Five Ìl of the MP suspension was diluted in 35 Ìl CaCl2 (2.5
mmol/L)-containing PBS. For MP staining, 5 Ìl Allophycocyanin
(APC)-labelled annexin V was added plus 5 Ìl of a cell-specific
monoclonal antibody or isotype-matched control antibodies. For
detection of EMP two different antibodies (CD144, CD62E) that
are both directed against antigens only expressed on endothelial
cells were used. CD144 is directed against vascular endothelial
(VE)-cadherin, which is believed to be constitutively exposed on
most types of endothelial cells, CD62E (E-selectin) is present only
on the surface of activated endothelial cells. The samples were
incubated in the dark for 15 minutes at room temperature. The
reaction in all samples was stopped with 900 Ìl calcium buffer (2.5
mmol/L), except for the annexin V control, to which citrate-
containing PBS (900 Ìl) was added. 
The MP were analyzed in a FACScan flow cytometer (Becton
Dickinson; Heidelberg, Germany) using Cell Quest Software
(Becton Dickinson; San Jose, CA, USA). Forward scatter (FSC)
and side scatter (SSC) were set at a logarithmic gain. The MP were
identified on the basis of their size and density and their capacity to
bind a cell-specific monoclonal antibody and annexin V. 
Cell-specific labelling with monoclonal antibodies was corrected
for identical concentrations of isotype-matched control antibodies
and annexin V measurements were corrected for autofluorescence.
The concentration of MP/L plasma was estimated according to
Berckmans et al. (14).
Statistics. The parametrically distributed data were expressed as
mean±standard deviation (SD). All the other data were presented
as the median ((Q1-Q3), interquartile range). The independent
variables were analyzed by the Mann-Whitney U-Test and all the
others by using the Chi-Square and Fisher's exact test. P-values
<0.05 were regarded as statistically significant. The data were
examined with SPSS (SPSS, Chicago, Illinois, USA) for Windows
(release 15.0).
Results
Study population. The mean age of the breast cancer
patients was 59.8±12.7 (34-85) years and did not differ
significantly from the controls (57.4±8.7 (42-71) years). The
hemoglobin (breast cancer: 13.7±1.1 g/dl (11.3-15.7);
controls: 13.7±0.8 g/dl (11.7-14.8)) and leukocyte levels
(breast cancer: 7.1±1.8 G/L (4.0-12.4); controls: 6.8±1.9
G/L (3.3-11.8)) also did not differ significantly. 
CEA and CA15-3. The CEA levels were elevated in breast
cancer patients compared to the controls (p<0.001; Table
I). There were significant differences in the CEA levels
within the study population: the median CEA values from
the breast cancer patients with distant metastases (M1) were
increased compared to the patients with T1 (p=0.009) or
the controls (p<0.001). 
Furthermore, the patients with T1 or T2 had higher CEA
levels compared to the controls (T1: p=0.001; T2: p<0.001).
Nine breast cancer patients and one control woman had
CEA values above the 95% confidence interval (22%
sensitivity, Figure 2). 
With regard to CA15-3, differences were also seen
between the breast cancer patients and the controls
(p=0.001) (Table I). 
The patients with advanced breast cancer (M1) had
elevated CA15-3 levels compared to the patients with T1
(p=0.042) or the controls (p=0.01). The breast cancer
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patients with T1 or T2 also had elevated CA15-3 levels
compared to the controls (T1: p=0.014; T2: p=0.012).
However, 10 breast cancer patients and one control woman
had CA15-3 levels above the 95% confidence interval
(24.4% sensitivity, Figure 2). 
Annexin V-positive microparticles. A wide range in the
numbers of circulating annexin V-binding MP in breast
cancer patients was found, without reaching a significant
difference between patients and controls (Table I, Figure
1a). The median value of the annexin V-positive MP
differed significantly in patients with low tumor size (T1)
compared to patients with distant metastases (M1) and
patients with high tumor size (T2) (p=0.017; p=0.02).
Altogether, 8 breast cancer patients and one control woman
had annexin V-positive MP above 95% confidence interval
(22% sensitivity; Figure 2). 
Endothelial cell-derived microparticles (EMP). In the
breast cancer patients and the controls, CD144-exposing
EMP were present, without significant differences (Table
I, Figure 1b). The patients with advanced breast cancer
(M1) had higher median values of CD144-positive MP
compared to the patients with T1 (p=0.045).
Furthermore, the patients with T2 had elevated CD144-
positive MP compared to T1 (p=0.006) or healthy
controls (p=0.018). 
Within the study population, only the patients with T2
had significantly higher numbers of CD62E-positive MP
compared to the patients with T1 (p=0.011).
Elevated numbers of EMP(CD144+) (above 95%
confidence interval), but not CD62E-positive EMP, were
detected in 5 breast cancer patients compared to one
control woman (14.6% sensitivity; Figure 2). 
Von Willebrand Factor antigen (vWF). The levels of vWF did
not differ between breast cancer patients and controls.
However, the breast cancer patients with T2 or M1 had
significantly higher vWF levels than the breast cancer
patients with T1 (p=0.019, p=0.001 respectively) and the
patients with distant metastases (M1) had higher levels
compared to the controls (p=0.005). A positive correlation
between vWF and CA15-3 levels was present in the breast
cancer patients (p=0.027, rho=0.432), whereas vWF and
numbers of EMP (CD144+, CD62E+) did not correlate. 
Leukocyte-derived microparticles (LMP). The numbers of CD45-
positive LMP were augmented by increasing tumor size and
were highest in the women with advanced breast cancer (M1)
(Table I, Figure 1c). Significant differences were present in the
breast cancer patients compared to the controls (p=0.02). The
patients with advanced breast cancer (M1) had higher median
values of CD45-positive LMP compared to the patients with T1
(p=0.028) or the healthy controls (p=0.031). Also the patients
with T2 had elevated numbers of LMP compared to the
controls (p=0.04). No correlation between leukocyte numbers
and levels of CD45-positive LMP was detected.
LMP numbers above 95% confidence interval were seen
in 5 breast cancer patients compared to one control woman
(12.2% sensitivity; Figure 2). 
Toth et al: Microparticles as Biomarkers in Breast Cancer
1109
Table I. CEA, CA15-3, EMP and LMP in the study population.
CEA CA15-3 Annexin V CD144 CD62E CD45
T1 1,3 17,2 3123 1481 466 188
(0-9) (6,9-32,2) (1532-5712) (817-2581) (130-1129) (102-287)
(0,90-1,78) (12,90-23,45) (2211-3937) (998-1943) (325-596) (157-221)
(0,42-9,02) (7,22-31,62) (1583-5588) (824-2561) (141-1078) (105-284)
T2 2,0 16,8 4912 2181 646 249
(1-56) (8,3-212,0) (1648-9665) (508-3850) (346-1192) (48-368)
(1,35-3,65) (13,70-31,10) (2648-8234) (1697-3227) (516-894) (149-318)
(0,80-56,10) (8,30-212,00) (1648-9665) (508-3850) (346-1192) (48-368)
M1 2,95 57,8 6592 2497 944 257
(1-70) (7,7-117,0) (2461-15970) (1065-4575) (240-1240) (126-647)
(1,90-21,58) (16,10-91,80) (3128-9576) (1304-4329) (263-1239) (213-449)
(1,30-70,40) (7,70-70,40) (2461-15970) (1065-4575) (240-1240) (126-647)
Control 0,7 11,97 3411 1674 424 167
(0-3) (6,6-95,1) (1343-6434) (166-3193) (192-1542) (60-310)
(0,34-1,02) (9,10-17,67) (2642-4465) (391-2196) (299-1066) (120-231)
(0,24-2,97) (6,60-84,87) (1503-6329) (203-3126) (197-1531) (62-305)
Median value, (minimum-maximum), (interquartile range), (5%-95% confidence interval) of CEA, CA15-3, Annexin V-, CD144-, CD62E- and
CD45-positive microparticles in the study population.
Discussion
Despite the relatively small size of the study population, our
data showed considerable differences in circulating
(subpopulations of) cell-derived MP in breast cancer
patients. The elevated numbers of CD45-positive MP
refelected the disease stage in the breast cancer patients and
differed significantly from the healthy controls. The EMP as
well as the vWF levels as markers of endothelial cell
activation, however, did not differ between the breast cancer
patients and controls.
At present, evidence is accumulating that cell-derived
vesicles released into the environment by cancer cells, i.e.
MP and exosomes, may contribute to cancer progression
and tumor outgrowth. Cell-derived vesicles from cancer
cells have been studied extensively in vitro and especially
MP are best known for their ability to initiate coagulation
by exposing “cancer procoagulant” or tissue factor, thereby
contributing to fibrin formation and promoting tumor
growth (15-17). In contrast, exosomes from tumor cells,
also called tumor cell-derived exosomes or texosomes,
suppress the immune response by exposure of Fas ligand,
thus killing T-cells (18). In addition, tumor cell-derived MP
and/or exosomes contain angiogenesis-promoting
phospholipids, such as sphingomyelin, high concentrations
of cytostatics which contribute to multi-drug resistance, and
several matrix metalloproteases that degrade the
environment (19-22). 
So far, no data have been reported on circulating LMP
and EMP in breast cancer patients. 
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Figure 1. a) Numbers of Annexin V-positive microparticles (x106/L) in
the study population. Data presented as scatter plot. Reference axis: 95%
confidence interval. Eight breast cancer patients and one control woman
had Annexin V-positive microparticles above 95% confidence interval
(22% sensitivity). b) Numbers of CD144-positive endothelial cell-derived
microparticles (x106/L) in the study population. Data presented as scatter
plot. Reference axis: 95% confidence interval. Elevated numbers of
CD144-positive microparticles (above 95% confidence interval) were
present in 5 breast cancer patients and one control woman (14.6%
sensitivity). c) Numbers of CD45-positive leukocyte-derived microparticles
(x106/L) in the study population. Data presented as scatter plot. Reference
axis: 95% confidence interval. Five breast cancer patients and one control
woman showed elevated levels of leukocyte-derived MP(CD45+) above
95% confidence interval (12.2% sensitivity).
The elevated numbers of CD144-positive EMP in the
patients with T2 and M1 are likely to be associated with
endothelial activation in vivo and, in addition, may reflect
procoagulant changes during tumor development. 
Additional evidence of endothelial activation has come
from several studies which indicated higher levels of
circulating vWF antigen in breast cancer patients compared
to women with benign tumors (12) or healthy controls (12,
23, 24). Rohsing et al. (12) demonstrated that increased
levels of vWF correlated with tumor progression in breast
cancer patients. Our present findings further support the
relationship between breast cancer and endothelial cell
activation. 
Kanazawa et al. (6) reported elevated levels of soluble
(non cell-associated) E-selectin in non-small cell lung cancer
patients compared to healthy subjects, suggesting that
endothelial cell activation may be a more general
phenomenom in cancer patients. Furthermore, Kanazawa et
al. also found elevated numbers of monocyte-derived MP in
cancer patients. The present study also demonstrated that
in breast cancer patients LMP are elevated. Their numbers
were not related to leukocyte counts, indicating that LMP
formation may be affected by cancer or cancer progression.
In vitro, LMP transfer tissue factor to developing thrombi
(25, 26) and are therefore believed to be involved in
thrombus formation (27). 
At present, the two most widely investigated clinical
tumor markers in breast cancer patients are CEA and
CA15-3. In particular CA15-3 is used to detect breast cancer
recurrences, evaluate therapeutic response of advanced
disease and prognosis. CA15-3 is a highly sensitive marker
for distant metastases, especially in bone and liver, but it is
not sensitive for locoregional or contralateral breast cancer. 
Focusing on the specificity-sensitivity profiles of the
established biomarkers CEA and CA15-3 in comparison
to circulating MP, LMP(CD45+) in particular might have
the potential to become a new biomarker in breast cancer
patients. 
Further investigations of the numbers of circulating
(subpopulations of) MP in breast cancer patients might
focus on preoperative evaluation of patients with different
disease states, postoperative determination of MP numbers
to establish individual baseline values and follow-up of
patients to evaluate their prognostic relevance. 
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